Medytox Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5
Ending by 2030
May 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 30, 2027The maintenance fee for Microorganism having ability to degrade ethanol and acetaldehyde, and composition and kit each including the same (US 11,801,276) comes due Apr 30, 2027. Unpaid by Nov 1, 2027, it lapses early.
- 2 fees due Jun 1 to 29, 2027 · next Jun 1
- 1 fee due Oct 16, 2027The maintenance fee for Long Lasting Effect of New Botulinum Toxin Formulations (US 11,957,741) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,220,780 | Pharmaceutical liquid composition of botulinum toxin with improved stability In force · From the USPTO record | In force | From the USPTO record | |
| US 8,993,268 | Method of producing Clostridium botulinum toxin using media containing plant-derived components and flexible closed container In force · From the USPTO record | In force | From the USPTO record | |
| US 10,293,034 | Pharmaceutical Liquid Composition of Botulinum Toxin with Improved Stability and Method of Use In force · Medium confidence | In force | Medium confidence | |
| US 8,617,568 | Pharmaceutical liquid composition of botulinum toxin with improved stability In force · From the USPTO record | In force | From the USPTO record | |
| US 12,274,739 | Pharmaceutical liquid composition of botulinum toxin with improved stability In force · From the USPTO record | In force | From the USPTO record | |
| US 8,920,795 | Lyophilized preparation of botulinum toxin In force · From the USPTO record | In force | From the USPTO record | |
| US 9,198,958 | Lyophilized preparation of botulinum toxin In force · From the USPTO record | In force | From the USPTO record | |
| US 10,143,728 | Long Lasting Effect of New Botulinum Toxin Formulations In force · High confidence | In force | High confidence | |
| US 11,590,212 | Long Lasting Effect of New Botulinum Toxin Formulations In force · High confidence | In force | High confidence | |
| US 11,596,673 | Long Lasting Effect of New Botulinum Toxin Formulations In force · High confidence | In force | High confidence |
Also on record, not counted in the 23: 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
10 pending · 4 abandoned · 4 no status recorded